Mycophenolic acid is used to improve oral bioavailability - royaldrugstore |
|
By: James Keneally Posted: 2014-02-15 00:29:13 |
|
Mycophenolic acid mycophenolate is an immunosuppressant drug used to prevent rejection in organ transplantation. It was initially marketed as the prodrug mycophenolate mofetil (MMF) to improve oral bioavailability. More recently, the salt mycophenolate sodium has also been introduced.Precautions & WarningsAdminister under the supervision of a health care provider experienced in immunosuppressive therapy and management of organ transplantation and in an equipped facility. Increased risk of lymphoma and increased susceptibility to infection may be related to immunosuppression.Administration is associated with increased risk of pregnancy loss and congenital malformations. Women of childbearing potential must use contraception.MonitorPerform CBCs weekly during the first month, twice monthly during the second and third months, then monthly through the first year. Monitor patient for signs and symptoms of bacterial, viral, or fungal infections, and for signs and symptoms of organ rejection.Over dosageNo reported cases. At plasma levels >100 mcg/ml, small amounts of the inactive metabolite may be removed by haemodialysis. Excretion of MPA may be enhanced by bile acid sequestrants (e.g. colestyramine).Special PrecautionsTeratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Active peptic ulcer disease. Severe renal impairment. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia.Drug interactionIncreased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.mofetil and mycophenolate sodium are not interchangeable. Perform CBCs; monitor for neutropenia.Other InteractionsFood reduces MPA peak serum levels by 40% and 33% following mycophenolate mofetil and mycophenolate sodium admin, respectively. Extent of absorption is not affected. Avoid cat's claw and echinacea as they have immunostimulant effects.ContraindicationsMycophenolic Acid and Pregnancy
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. Mycophenolic Acid and Lactation Contraindicated in lactation Safety and efficacy in cardiac or hepatic transplants not established. Mycophenolic Acid and Geriatic Use with caution because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.Storage:Store at room temperature between 15 to 300c. Protect from heat, light and moisture. Keep away from reach of children. |
| Trackback url: https://article.abc-directory.com/article/9705 |